We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
176
PUT
DELISTED
Dynavax Technologies
DVAX
$211K 0.01%
219
– –
PCRX icon
177
Pacira BioSciences
PCRX
$1.06B
$209K 0.01%
+4,390
New +$204K
AMAG
178
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
$193K 0.01%
105
-4
-4% -$79
CSBR icon
179
Champions Oncology
CSBR
$76.8M
$184K 0.01%
71,700
– –
ADXS
180
CALL
DELISTED
Advaxis Inc
ADXS
$175K 0.01%
18
– –
RXDX
181
CALL
DELISTED
Ignyta, Inc.
RXDX
$170K 0.01%
164
+21
+15% +$171
GRDX
182
GridAI Technologies Corp
GRDX
$20.4M
– –
-1
Closed -$471K
MNKD icon
183
CALL
MannKind Corp
MNKD
$1.22B
$159K 0.01%
1,127
– –
GALT icon
184
PUT
Galectin Therapeutics
GALT
$228M
$158K 0.01%
641
-199
-24% -$530
PALI icon
185
PUT
Palisade Bio
PALI
$348M
– –
0
– –
NSPRZ
186
DELISTED
InspireMD, Inc. Series B Warrants
NSPRZ
$155K 0.01%
+2,002,348
New +$262K
ATOS icon
187
Atossa Therapeutics
ATOS
$23.7M
$150K 0.01%
+1,617
New +$166K
NSPRW
188
DELISTED
InspireMD, Inc. Warrants
NSPRW
$145K 0.01%
1,209,425
-5,500
-0.5% -$625
PARN
189
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$143K 0.01%
170,000
-33,549
-16% -$28.2K
IOVA icon
190
PUT
Iovance Biotherapeutics
IOVA
$2.08B
$140K 0.01%
+195
New +$1.24K
ADXS
191
DELISTED
Advaxis Inc
ADXS
$135K 0.01%
+1,382
New +$162K
SLNO
192
DELISTED
Soleno Therapeutics
SLNO
$127K 0.01%
3,308
+189
+6% +$8.76K
WINT
193
DELISTED
Windtree Therapeutics Inc
WINT
$112K 0.01%
345,712
+58,190
+20% +$67.8K
CYTO
194
DELISTED
Altamira Therapeutics Ltd
CYTO
$103K 0.01%
2
– –
TOVX icon
195
Theriva Biologics
TOVX
$9.69M
$95K 0.01%
19
-143
-88% -$712K
CRIS icon
196
Curis
CRIS
$9.78M
$91K 0.01%
+24
New +$100K
CRIS icon
197
PUT
Curis
CRIS
$9.78M
– –
0
– –
RNVA
198
DELISTED
Rennova Health, Inc.
RNVA
$75K ﹤0.01%
13,257
+11,591
+696% +$123K
BCLI
199
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$70K ﹤0.01%
1,115
-3,521
-76% -$217K
CSCI
200
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$67K ﹤0.01%
+673
New +$107K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.